1. Anti-infection Cell Cycle/DNA Damage
  2. CMV DNA/RNA Synthesis G-quadruplex
  3. Braco-19

Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Braco-19

Braco-19 構造式

CAS 番号 : 351351-75-2

容量 価格(税別) 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 183 在庫あり
Solution
10 mM * 1 mL in DMSO USD 183 在庫あり
Solid
5 mg $140 在庫あり
10 mg $230 在庫あり
25 mg $500 在庫あり
50 mg $820 在庫あり
100 mg $1380 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 5 publication(s) in Google Scholar

Other Forms of Braco-19:

Top Publications Citing Use of Products

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示:

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor[1][2].

IC50 & Target

IC50: telomerase/telomere[1]

Cellular Effect
Cell Line Type Value Description References
A-431 IC50
15.8 3
Compound: 7
Cytotoxicity against ovarian carcinoma A431 cell lines
Cytotoxicity against ovarian carcinoma A431 cell lines
[PMID: 14521409]
A2780 IC50
0.1 3
Compound: 1
Inhibition of telomerase in human A2780 cells by TRAP assay
Inhibition of telomerase in human A2780 cells by TRAP assay
[PMID: 19726112]
A2780 IC50
10 3
Compound: 7
Cytotoxicity against ovarian carcinoma A2780 cell lines
Cytotoxicity against ovarian carcinoma A2780 cell lines
[PMID: 14521409]
A2780 EC50
113 1
Compound: 1a
Inhibition of telomerase activity from human A2780 cells
Inhibition of telomerase activity from human A2780 cells
[PMID: 16420044]
A2780 IC50
0.1 3
Compound: 1
Inhibition of telomerase in human A2780 cells by TRAP assay
Inhibition of telomerase in human A2780 cells by TRAP assay
[PMID: 19726112]
A549 IC50
0.09 3
Compound: BRACO-19
Inhibition of human telomerase in A549 cells by TRAP assay
Inhibition of human telomerase in A549 cells by TRAP assay
[PMID: 19467742]
A2780 IC50
0.1 3
Compound: 1
Inhibition of telomerase in human A2780 cells by TRAP assay
Inhibition of telomerase in human A2780 cells by TRAP assay
[PMID: 19726112]
A549 IC50
2.4 3
Compound: BRACO-19
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 19053833]
A-431 IC50
15.8 3
Compound: 7
Cytotoxicity against ovarian carcinoma A431 cell lines
Cytotoxicity against ovarian carcinoma A431 cell lines
[PMID: 14521409]
A549 IC50
2.4 3
Compound: BRACO-19
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 19053833]
A549 IC50
2.42 3
Compound: 1
Growth inhibition of human A549 cells by SRB assay
Growth inhibition of human A549 cells by SRB assay
[PMID: 17276687]
A2780 IC50
10 3
Compound: 7
Cytotoxicity against ovarian carcinoma A2780 cell lines
Cytotoxicity against ovarian carcinoma A2780 cell lines
[PMID: 14521409]
A549 IC50
0.09 3
Compound: BRACO-19
Inhibition of human telomerase in A549 cells by TRAP assay
Inhibition of human telomerase in A549 cells by TRAP assay
[PMID: 19467742]
DU-145 IC50
2.3 3
Compound: 1
Growth inhibition of human DU145 cells by SRB assay
Growth inhibition of human DU145 cells by SRB assay
[PMID: 17276687]
A549 IC50
2.42 3
Compound: 1
Growth inhibition of human A549 cells by SRB assay
Growth inhibition of human A549 cells by SRB assay
[PMID: 17276687]
A549 IC50
2.4 3
Compound: BRACO-19
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
[PMID: 19053833]
GIST882 IC50
> 25 3
Compound: BRACO-19
Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
[PMID: 19469547]
A549 IC50
0.09 3
Compound: BRACO-19
Inhibition of human telomerase in A549 cells by TRAP assay
Inhibition of human telomerase in A549 cells by TRAP assay
[PMID: 19467742]
A549 IC50
2.42 3
Compound: 1
Growth inhibition of human A549 cells by SRB assay
Growth inhibition of human A549 cells by SRB assay
[PMID: 17276687]
DU-145 IC50
2.3 3
Compound: 1
Growth inhibition of human DU145 cells by SRB assay
Growth inhibition of human DU145 cells by SRB assay
[PMID: 17276687]
HEK-293T IC50
45 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay
Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay
[PMID: 17954919]
HEK-293T IC50
65 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay
Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay
[PMID: 17954919]
GIST882 IC50
>25 3
Compound: BRACO-19
Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
[PMID: 19469547]
HeLa IC50
5.25 3
Compound: BRACO19
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 34124673]
DU-145 IC50
2.3 3
Compound: 1
Growth inhibition of human DU145 cells by SRB assay
Growth inhibition of human DU145 cells by SRB assay
[PMID: 17276687]
HEK-293T IC50
830 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay
Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay
[PMID: 17954919]
GIST882 IC50
> 25 3
Compound: BRACO-19
Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
Antiproliferative activity against human GIST882 cells after 96 hrs by SRB assay
[PMID: 19469547]
HeLa IC50
5.25 3
Compound: BRACO19
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 34124673]
HGC-27 IC50
2.3 3
Compound: BRACO-19
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
[PMID: 29724653]
HGC-27 IC50
2.6 3
Compound: BRACO-19
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
[PMID: 19469547]
HEK-293T IC50
45 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay
Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay
[PMID: 17954919]
HGC-27 IC50
2.3 3
Compound: BRACO-19
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
[PMID: 29724653]
HGC-27 IC50
2.6 3
Compound: BRACO-19
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
[PMID: 19469547]
HEK-293T IC50
65 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay
Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay
[PMID: 17954919]
HT-29 IC50
2.7 3
Compound: BRACO-19
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 19469547]
HT-29 IC50
2.7 3
Compound: BRACO-19
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 29724653]
HEK-293T IC50
830 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay
Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay
[PMID: 17954919]
HT-29 IC50
2.7 3
Compound: BRACO-19
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 29724653]
HGC-27 IC50
2.3 3
Compound: BRACO-19
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
[PMID: 29724653]
IMR-90 IC50
>25 3
Compound: 1a
Cytotoxicity in human IMR90 cells by SRB assay
Cytotoxicity in human IMR90 cells by SRB assay
[PMID: 16420044]
HT-29 IC50
2.7 3
Compound: BRACO-19
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 19469547]
HGC-27 IC50
2.6 3
Compound: BRACO-19
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
Antiproliferative activity against human HGC27 cells after 96 hrs by SRB assay
[PMID: 19469547]
IMR-90 IC50
> 25 3
Compound: 1a
Cytotoxicity in human IMR90 cells by SRB assay
Cytotoxicity in human IMR90 cells by SRB assay
[PMID: 16420044]
HEK-293T IC50
45 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay
Inhibition of human telomerase expressed in HEK293T cells treated before telomerase elongation by telomeric repeat amplification protocol assay
[PMID: 17954919]
HT-29 IC50
2.7 3
Compound: BRACO-19
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 19469547]
MCF7 IC50
2.2 3
Compound: BRACO-19
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 29724653]
MCF7 IC50
2.2 3
Compound: BRACO-19
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 19469547]
HT-29 IC50
2.7 3
Compound: BRACO-19
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay
[PMID: 29724653]
MCF7 IC50
2.2 3
Compound: BRACO-19
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 19469547]
MCF7 IC50
2.2 3
Compound: BRACO-19
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 29724653]
MCF7 IC50
2.5 3
Compound: BRACO-19
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 19053833]
HeLa IC50
5.25 3
Compound: BRACO19
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 34124673]
MCF7 IC50
2.5 3
Compound: BRACO-19
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 19053833]
MCF7 IC50
2.53 3
Compound: 1
Growth inhibition of human MCF7 cells by SRB assay
Growth inhibition of human MCF7 cells by SRB assay
[PMID: 17276687]
HEK-293T IC50
65 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay
Inhibition of human telomerase expressed in HEK293T cells treated after telomerase elongation by telomeric repeat amplification protocol assay
[PMID: 17954919]
IMR-90 IC50
> 25 3
Compound: 1a
Cytotoxicity in human IMR90 cells by SRB assay
Cytotoxicity in human IMR90 cells by SRB assay
[PMID: 16420044]
MCF7 IC50
2.53 3
Compound: 1
Growth inhibition of human MCF7 cells by SRB assay
Growth inhibition of human MCF7 cells by SRB assay
[PMID: 17276687]
MRC5 IC50
8.33 3
Compound: BRACO-19
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 29323491]
A2780 EC50
113 1
Compound: 1a
Inhibition of telomerase activity from human A2780 cells
Inhibition of telomerase activity from human A2780 cells
[PMID: 16420044]
MCF7 IC50
2.2 3
Compound: BRACO-19
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 19469547]
U2OS IC50
> 40 3
Compound: BRACO19
Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
[PMID: 31759730]
MCF7 IC50
2.2 3
Compound: BRACO-19
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 29724653]
WI-38 IC50
10.7 3
Compound: BRACO-19
Cytotoxicity against human WI38 cells after 96 hrs by SRB assay
Cytotoxicity against human WI38 cells after 96 hrs by SRB assay
[PMID: 19053833]
MRC5 IC50
8.33 3
Compound: BRACO-19
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 29323491]
MCF7 IC50
2.5 3
Compound: BRACO-19
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
[PMID: 19053833]
HEK-293T IC50
830 1
Compound: BRACO-19
Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay
Inhibition of human telomerase expressed in HEK293T cells in presence of primer (T2AG3)3 by primer extension assay
[PMID: 17954919]
U2OS IC50
>40 3
Compound: BRACO19
Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
[PMID: 31759730]
MCF7 IC50
2.53 3
Compound: 1
Growth inhibition of human MCF7 cells by SRB assay
Growth inhibition of human MCF7 cells by SRB assay
[PMID: 17276687]
WI-38 IC50
10.7 3
Compound: BRACO-19
Cytotoxicity against human WI38 cells after 96 hrs by SRB assay
Cytotoxicity against human WI38 cells after 96 hrs by SRB assay
[PMID: 19053833]
MRC5 IC50
8.3 3
Compound: Braco-19
Cytotoxicity against human MRC5 cells
Cytotoxicity against human MRC5 cells
[PMID: 38971047]
MRC5 IC50
8.33 3
Compound: BRACO-19
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 29323491]
U2OS IC50
> 40 3
Compound: BRACO19
Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay
[PMID: 31759730]
WI-38 IC50
10.7 3
Compound: BRACO-19
Cytotoxicity against human WI38 cells after 96 hrs by SRB assay
Cytotoxicity against human WI38 cells after 96 hrs by SRB assay
[PMID: 19053833]
体外実験

Braco-19, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication[2].
BRACO-19 (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC50 for BRACO-19 in UXF1138L cells is 2.5 μM, the IC100 is 5 μM[1].
BRACO-19 (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses[1].
BRACO-19 (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells[2].
BRACO-19 (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HEK 293 cells
Concentration: 20 μM; 40 μM
Incubation Time: 24 hours
Result: Displayed low cytotoxicity and decreased the eGFP fluorescence.
体内実験

BRACO-19 (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts[1].
BRACO-19 (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Established UXF1138LX Xenografts in nude mice[1]
Dosage: 2 mg/kg
Administration: Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments
Result: Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control.
分子量

593.76

分子式

C35H43N7O2

CAS 番号
Appearance

Solid

Color

Brown to orange

SMILES

CN(C1=CC=C(NC2=C(C=CC(NC(CCN3CCCC3)=O)=C4)C4=NC5=CC(NC(CCN6CCCC6)=O)=CC=C52)C=C1)C

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

DMSO : 33.33 mg/mL (56.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6842 mL 8.4209 mL 16.8418 mL
5 mM 0.3368 mL 1.6842 mL 3.3684 mL
10 mM 0.1684 mL 0.8421 mL 1.6842 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます:C1V1 = C2V2

濃度 (開始)

C1

×
体積 (開始)

V1

=
濃度 (終了)

C2

×
体積 (終了)

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (4.21 mM); Clear solution; Need ultrasonic

    This protocol yields a clear solution of 2.5 mg/mL.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (4.21 mM); Clear solution; Need ultrasonic

    This protocol yields a clear solution of 2.5 mg/mL.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション

純度: 98.01%

参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.6842 mL 8.4209 mL 16.8418 mL 42.1046 mL
5 mM 0.3368 mL 1.6842 mL 3.3684 mL 8.4209 mL
10 mM 0.1684 mL 0.8421 mL 1.6842 mL 4.2105 mL
15 mM 0.1123 mL 0.5614 mL 1.1228 mL 2.8070 mL
20 mM 0.0842 mL 0.4210 mL 0.8421 mL 2.1052 mL
25 mM 0.0674 mL 0.3368 mL 0.6737 mL 1.6842 mL
30 mM 0.0561 mL 0.2807 mL 0.5614 mL 1.4035 mL
40 mM 0.0421 mL 0.2105 mL 0.4210 mL 1.0526 mL
50 mM 0.0337 mL 0.1684 mL 0.3368 mL 0.8421 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます:C1V1 = C2V2

濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

 

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Braco-19
製品番号:
HY-15523
数量:
MCE 日本正規代理店: